Empagliflozin; Sodium Glucose Transporter 2 inhibitor; Dipeptidyl-peptidase 4 inhibitor; Glucagon-like peptide 1 agonist
Проводит Boehringer Ingelheim
Страница компанииCORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03807440/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 4083 чел. во всех странах исследования.
- Центров в реестре: 54 в 30 городах. Список — ниже на странице.
- Плановая дата окончания (08.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 3
Критерии включения
- Written informed consent prior to participation
- Female and male patients age ≥ 18 years
- Patients with T2D diagnosis
- Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
- Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1
Критерии невключения
- Patients age < 18 years
- Patients with diagnosis of other types of diabetes than T2D
- Patients who do not provide written consent to the terms of the study
Источник: ClinicalTrials.gov, NCT03807440 · запись обновлена в реестре 1 декабря 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 40
- Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist — At study index date 1 (i.e. between September 2018 and December 2018).
- Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist — At study index date 1 (i.e. between September 2018 and December 2018).
- Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist — At study index date 1 (i.e. between September 2018 and December 2018).
- Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist — At study index date 1 (i.e. between September 2018 and December 2018).
Цель исследования
This is a non-interventional study using existing data including medical chart review.
Где проходит
54 центра в 30 городах- City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082
- Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042
- Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032
- SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080
- Vessel Clinic, Center Nr.: 70011
- ГБУЗ города Москвы «Городская клиническая больница имени В.В. Вересаева ДЗМ»
- ГБУЗ города Москвы «Городская поликлиника № 22 ДЗМ»
- ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России
- Federal State Educational Institution of Higher Education «North-West State Medical University named after I.I. Mechnikov» of the Ministry of Health of the Russian Federation
- Medilux-TM, Center Nr.: 70005
- Zabotlivyi Doktor, Center Nr.: 70016
- ООО «АнтМед»
- СПб ГБУЗ «Городская Покровская больница»
- ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России
- ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03807440 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.